2 March 2010– AstraZeneca will move to Mölndal – staff meeting –900 people to lose their jobs2 March 2010– Allan Larsson appointed chief negotiator and todevelop a Life Science concept by FIRS(Forsknings- och Innovationsrådet i Skåne =Research and Innovation Council Skåne)14 January 2011– Mats Paulsson´s Foundation announced. 100 miljSEK donated and surplus reinvested into researchand innovation.10 January 2012– Medicon Village being launchedFrom bad to good…
AstraZeneca exit from LundAchievements and learningsGovernance: Accountability formanaging the change and externalstakeholders (regional partners, mediaetc.) very unclear the first 5 months.Great improvement during autumn 2010when leadership team was empoweredand resources made available.Success factors•Transformation from global to local•External, pro-active communication plan•Local accountabilities with senior teammembers; well defined objectives;budget/resource; focus on solutions andtransparency•Internal AZ project teams working closely withLCT on well defined projects•LCT culture and behaviours: Silos broken, onefor all – all for one; breathe the air in Lund!Engagement: Critical for keeping upthe spirit and finding the strength andcommitment to deliver the objectives in adifficult situation.Success factors•Dedicated local leaders•A variety of events and activities were arrangedboth by LCT and functions• Career support activities• Focus on motivation and well-being•Site sale – an extremely importantachievement!• Handover project (Buildings/instruments,IS/IT, competence)5Lund LCT | October 2011Never underestimatepeoplesʼ drivingforce to do a goodjob. But donʼt take itfor granted!
Never underestimatepeoplesʼ drivingforce to do a goodjob. But donʼt takeit for granted!AstraZeneca exit from LundAchievements and learningsRecruitment and relocation:Functional reorganisations in parallel withmoving a business with people, projects andequipment is more complicated than one canever imagine•New organisation in Mölndal not in place toprovide pull until late 2010/early 2011•More people may have moved withfirmer/faster processRedundancy: Redundancy/early retirementpackages; people had to wait too long forinformation, but perceived as generous when itcame•Local HR Center an excellent improvementwhen in place, but would have been even betterif also early retirement was managed locally•Local career support activities outstanding!Communications: After announcementof the site closure and during a large part of2010 the general perception was that there wasno communication by global R&D.Initially the unions “provided the lifeline” andlocal functional leadership provided the stability.From Q3 2010 and forward a strongimprovement was seen in communication whenlocal ownership and resources came in place.Success factors•Visible local leadership (by LCT and functions)provided clarity and a sense of security•Several well-managed communicationchannels6Lund LCT | October 2011 R&D | PMO
Executive summary• 85% had moved in August 201180% of staff signed up have their work‐place in Mölndal by end of August 2011 and all relocated by end of October 2011 • 85% had a plan75% of people made redundant have a plan for new opportunities within 6 months• ready to hand over before December 2011. Steering group decided on January 2012.Lund site transferred to new owners at the latest by end of December 2011• Survey among employees > 90 % agreed or strongly agreedExiting Lund perceived to be done in a responsible way with respect for employees• Outstanding (Swedish independent analysis by Mediapilot AB)Maintain corporate reputationLund LCT achievements and deliverables7Lund LCT | October 2011Objectives Results
Swedish Independent media analysis by Mediapilot AB• ”The conclusion is that AstraZeneca in many ways havesucceeded in turning negative news to positive publicity byshowing responsibility and understanding of their employees.Even though the news around the site closure are negativeper se, there has been a lot of positive outcomes.”1 March 2010 – 30 September 20118Lund LCT | October 2011 R&D | PMO
What has happened with the employees Nov 2011?892 employees in Lund March 2, 20109Moved to Mölndal (23%)(40% of 520 that were asked)Retired (12,1%)External – New Company (32,3%)Business start up (7,7%)Education(8,2%)Active job hunters ordecided to take a break(16,5%)More than 80% know their future!
MediconVillageFor people´s health andwell-being
Medicon VillageResearch, innovation and businessESS Head Office Conference and restaurantAppr. 30 life science companies(B2B)Lund Life Science Incubatorappr. 20 companiesCancer Centre Region Skåne BiobankInnovation partners and institutesPrimary Care SkåneScience Support & labshop
Facts & FiguresMarch 2013• Launched 10th January 2012• Former AstraZeneca site• Laboratories 30 000 m2• Offices, Conference 50 000 m2• >600 members• An additional 200 cancer researchers from June 2013• >75 organizations– 22 product companies– 51 service companies/providers– 2 institutes13
Life ScienceForesight Institute Regionalt biobankscentrum
Medicon Village members(product and R&D companies)Cancer Resp./inflam. Other indications PreventionMaterialDiagnostics Treatment Diagnostics Treatment Prevention Diagnostics Care Treatment OtherChemistryMedtechE‐Health/m‐healthNano‐medicineBiotechPharma2013 03 10
Entire value chain –embracing the whole individualAt Medicon Village we want to create an environmentwhere research, innovation and entrepreneurship worktogether to create value for people’s health andwellbeing
What makes Medicon Village unique?• A development company owned byMats Paulsson´s Foundation forresearch, innovation and societaldevelopment• Profits reinvested in research andinnovation• Members moving into premisesready to use - complete R&D site• The entire value chain, fromresearchers to innovators andbusinessmen are represented• Giving small companies the sameadvantages that can normally onlybe enjoyed by large companiesTRIPLE HELIX in actionBOARD MEMBERS OF MATS PAULSSON´S FOUNDATION:Allan Larsson, former chairman of Lund UniversityPia Kinhult, First Governor ,Chair of the Regional Executive CommitteeGöran Grosskopf, Mats Paulsson´s FoundationMats Paulsson, Mats Paulsson´s FoundationPer Eriksson, Vice-Chancellor, Lund University
Prevention Diagnosis Treatment CareFrom basic research tomature companiescovering the entire valuechainBody and Mind inseparable
Lund University & Medicon VillageCreating one of strongest cancerresearch units in Europe
MobileHealthProcessingKnowledge1+1=5Processing start-up incubationNanomedicincenterOne stop shop:Max IVESSScience VillageScandinaviaExternalization&PartnershipsDrug Delivery InstituteMove the challenge at Medicon VillageHealthInformaticsMedicon Village ClinicsMediconVillageFoundationMediconSkillsCentre
A world class player within LifeScienceExternalization is animportant part of MediconVillage’s concept andinternational partnershipsare being worked on,both in the east and overthe Atlantics to the west.
World class cluster criteriaJones Lang LaSalle (2011)Situation in Medicon Valley?• Educated workforce• Venture and investment capital• Centers of excellence and innovation• Industry-friendly political structures• Institutions of higher learning• Target oriented economic development incentives• Patent protection• Supporting infrastructure
Twinning Life Science clusters- between similar eco systems
Memorandum of Understanding: WalesThe participants will strongly pursue for mutual benefit the potential for collaboration in the field of Life Sciences,technology, innovation, research and development and their commercial exploitation.The participants will promote the establishment of co-operative relationships between companies, organisations,universities and investors in their respective countries.The participants will promote business and trade opportunities and provide practical assistance to organisations,universities and other innovative enterprises wishing to collaborate or locate in the other region.The participants will promote international business development, encouraging innovation and research collaborationsand facilitating the identification of partners, collaborators and investors between the regions.The participants will invite the other region to participate in relevant conferences in the field of Life Sciences.The participants will seek to maintain regular contact to facilitate consultations on the exchanges and cooperation aswell as matters of common concern.The participants will also seek to involve other parties in the implementation of this memorandum.
Memorandum of Understanding:Wales Life Science Cluster and Medicon VillageLaunch 19 March 2013Growthvia TwinningGrowthvia TwinningConnectingConnectingPromotingPromotingSupportingSupportingPartneringPartneringEnjoyingEnjoyingExcellingExcellingCo‐operatingCo‐operatingCollaboratingCollaboratingConsultingConsultingDevelopingDevelopingEncouragingEncouragingFacilitatingFacilitatingParticipatingParticipatingImplementingImplementingInvolvingInvolvingExchangingExchangingAssistingAssisting
Twin Clusters (1) –between similar eco systems• Areas of interest:• Innovation - Process and Product• Cancer• Diabetes• Neuroscience• Translational research• Philanthropy and Venture Capital• Cooperation/invest perspective:• Promote the establishment of co-operative relationships between companiesand organizations in our respective countries.• Promote international business development, encouraging innovation and research collaborationsbetween the two regions.• Facilitate the identification of partners, collaborators and (international) investors to provideinternational business development.• Explore opportunities in respective innovation systems
Twin Clusters (2)• Company perspective:• Co-incubation of start-ups• Port of entry to respective country for growth of a company• Promote business opportunities and access to trade opportunities in respective countries.• Research perspective:• Facilitate research collaboration regarding e.g. ESS and respective university – bridging betweenteams and individuals• Bio banks• Stimulate collaboration cross-institutions– Including hospitals and healthcare– Identifying partners
Lund Life Science Incubator is a business incubator which helpsentrepreneurs and small companies within the field of Life Science todevelop and commercialize their ideasLund Life Science IncubatorStructural Biology andStructure-Based DrugDesign OutsourcingA research and developmentcompany dedicated to find newways to promote better health forpatients with autoimmunedisordersProvides life science anddrug developmentconsultancy with anemphasis on biology andtranslational science.Developes BioBarrier™,an effective and userfriendly post-surgicaladhesion barrier spray.The incubator hosts both product companies and service companies,working in different fields and in different stages of development. Thisbreadth provides an dynamic environment and knowledge exchange.
The European Spallation SourceThe European Spallation Source (ESS) is a multi-disciplinary researchcentre based on the world’s most powerful neutron source. It is aEuropean project with, at present, 17 Partner Countries, with Sweden andDenmark as host nations.The facility will be around 30 times brighter than todays leading facilities,enabling new opportunities for researchers in the fields of life sciences,energy, environmental technology, cultural heritage and fundamentalphysics.The European SpallationSource is one of the largestscience and technologyinfrastructure projectsbeing built today.